ArticleGynecologic oncology reports2026
Long-term remission after multimodal therapy in metastatic small cell carcinoma of the ovary, hypercalcemic type: A case report.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), is an extremely rare and aggressive ovarian malignancy that predominantly affects young women. Prognosis is stage-dependent, with a 5-year overall survival (OS) of approximately 20% in advanced stages (II-IV). Treatment typically involves a multimodal approach.Case Presentation.We present the case of a 24-year-old woman diagnosed with stage IV SCCOHT presenting multiple pulmonary nodules and enlarged retroperitoneal lymph nodes. Following standard treatment protocols, including surgery, chemotherapy and high-dose chemotherapy with autologous stem cell rescue, she achieved a complete response and has remained in remission for over five years despite initial pulmonary metastases. Given the rarity of SCCOHT, management was guided by recommendations and through the expertise of a national reference center. Conclusion: This case highlights that, while durable remission is possible, intensive multimodal therapy is required, and SCCOHT survivors face significant long-term challenges. A comprehensive, multidisciplinary survivorship approach is essential to optimize long-term outcomes and quality of life, in accordance with current guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.